WATERTOWN, Mass. – C4 Therapeutics (C4T) today announced the transformation of its ongoing research and development partnership with Roche focusing on new cancer treatments based on C4T’s targeted protein degradation technology.
“We are excited to see our partnership with Roche evolve and further accelerate our efforts to bring degrader-based medicines into the clinic,”
said Andrew Phillips, PhD, President and CEO of C4 Therapeutics. “Roche has been a valued and excellent partner since we started our collaboration in 2016. This transformed partnership reflects how much both parties believe in the potential of degraders as a new treatment modality for patients.”
Under the terms of the expansion, C4T will lead efforts from discovery through defined preclinical or early clinical milestones, depending on the program. Upon C4T reaching these milestone events, Roche will have exclusive options for worldwide rights to continue development and commercialize drugs from these programs. In addition, C4T will have the option to co-develop and co-promote in the U.S. on selected programs. C4T will receive a significant upfront payment and near-term preclinical milestones. Upon success C4T may also receive royalties and potential clinical, regulatory, and commercial milestone payments totaling over $900 million.
About C4 Therapeutics
C4 Therapeutics (C4T) is pioneering a new class of small-molecule drugs that selectively target disease-relevant proteins for degradation using the innate machinery of the cell. This targeted protein degradation approach has the potential to treat a range of diseases and offers advantages over traditional drugs, such as potential to minimize drug resistance, de-risked starting points, high potency and specificity. To learn more about C4 Therapeutics, visit www.C4Therapeutics.com.